Glucantime

 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2009
2009
Leishmaniasis is caused by species of the protozoan parasite Leishmania. It is the third most important vector-borne disease and… (More)
  • table 3
  • table 1
  • table 4
  • table 2
  • table 5
Is this relevant?
2007
2007
Cutaneous leishmaniasis (CL) is a major health problem in endemic areas of Iran. The pentavalent antimony (SbV) based drug… (More)
  • figure 1
  • table 1
Is this relevant?
Highly Cited
2006
Highly Cited
2006
BACKGROUND Recent circumstantial evidence suggests that an increasing number of Iranian patients with cutaneous leishmaniasis are… (More)
  • figure 1
  • table 1
  • table 2
  • figure 2
  • figure 3
Is this relevant?
2006
2006
INTRODUCTION Cutaneous leishmaniasis is a common parasitic disease in Iran, especially in Isfahan. First line treatment for this… (More)
Is this relevant?
2005
2005
UNLABELLED Glucantime is the most common stibied derivative used to treat cutaneous leishmaniasis (CL) in Tunisia; however… (More)
Is this relevant?
2004
2004
BACKGROUND Cutaneous leishmaniasis (CL) is a parasitic disease caused by Leishmania species. There is a need for more effective… (More)
Is this relevant?
2002
2002
BACKGROUND Cutaneous leishmaniasis is a common disease in Iran, particularly in Kerman province. It usually occurs via the bite… (More)
Is this relevant?
1998
1998
Meglumine antimonate (Glucantime), a drug of choice for the treatment of leishmaniasis, is produced by the reaction of… (More)
Is this relevant?
Highly Cited
1998
Highly Cited
1998
A nested PCR was developed to amplify the variable region of the kinetoplast minicircles of all Leishmania species which infect… (More)
  • figure 1
  • figure 2
  • table 1
Is this relevant?
Highly Cited
1990
Highly Cited
1990
Sixty-six Guatemalans with parasitologically proven cutaneous leishmaniasis were randomly and equally divided into 3 treatment… (More)
Is this relevant?